FDA approves sNDA for pediatric autism drug ABILIFY

Links shared publicly online about this topic.

1,587
total visits

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

View full resource at news-medical.net

Tags: Antipsychotic Medication, Disease and Condition, Drug, Pharma, Children's Health, FDA, Abilify, Bristol-Myers Squibb

Most Recently Shared on November 21, 2009 at 9:30 am By:

News-Medical.Net

Stroke News: FDA approves sNDA for pediatric autism drug ABILIFY: Bristol-Myers Squibb Company and .. http://twurl.nl/485sb6

3 years ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

drugs.com — “Abilify (aripiprazole) is used to treat irritability associated with autistic disorder in pediatric patients. Includes Abilify side effects, interactions and indications.” View full resource at drugs.com